New Hope in the Fight Against Cancer?
In the ongoing battle against cancer, it sometimes feels like we’re taking one step forward and two steps back.
Surgery, chemotherapy, and radiation—the mainstream treatments that have been the backbone of cancer care for decades—often do more harm than good, leaving patients weakened, sick, and struggling to maintain their quality of life.
It’s a far cry from a cure, and it’s no wonder that patients and their loved ones are desperate for new approaches.
That’s why any breakthrough in cancer research, no matter how small, is cause for celebration. And a new study from Goethe University Frankfurt is shedding light on new breaking research in the cancer world.
Thalidomide. If the name sounds familiar, it’s because thalidomide has a dark past. Originally marketed as a sedative and sleeping pill in the 1950s, it soon became apparent that the drug caused severe birth defects when taken by pregnant women.
But in recent years, researchers have been taking a second look at thalidomide and its potential to fight cancer.
The key, it turns out, lies in thalidomide’s ability to act as a “molecular glue.” It can grab hold of two proteins and pull them together, which can have profound effects on the cell.
One of these proteins is a kind of “labeling machine” that marks other proteins for destruction. When thalidomide brings this labeling machine into contact with a specific protein, it’s like putting a “WASTE” label on it—the cell’s disposal system recognizes the label and shreds the protein.
This mechanism has caught the attention of cancer researchers because cancer cells rely on certain proteins to survive. If we could find a way to systematically target and destroy these proteins, it could be a game-changer in the fight against the disease.
That’s where the new study comes in. Researchers produced a range of thalidomide derivatives and tested them to see which proteins they were effective against. They found three derivatives that were able to mark a protein called BCL-2 for degradation.
BCL-2 is important because it prevents cancer cells from self-destructing—so if it’s eliminated, the cancer cells die.
What’s exciting about this finding is that BCL-2 is often mutated in cancer cells, making them resistant to existing drugs that try to inhibit its function. But the thalidomide derivatives were able to mark even the mutated form of BCL-2 for destruction, suggesting that they could potentially overcome this resistance.
The researchers also tested their substances in fruit flies with cancerous cells and found that the treated flies had a much higher survival rate.
While these results are still in the early stages, they offer a glimpse of a potential new approach to cancer treatment.
Of course, there’s still a long way to go before thalidomide derivatives could be used in human patients. And, considering the drug’s dark past, long-term studies need to be executed and evaluated.
Even the study’s lead author, Dr. Xinlai Cheng, cautions against getting too excited just yet, noting that these findings are still basic research and it’s unclear whether they will prove effective in practice.
But at e-Alert, we strive to always provide you with the latest breaking research and full transparency. We’ll continue to keep you updated as new studies come out—regardless of their outcome.
The dark history of thalidomide may never be fully erased, but could its potential to help in the cancer fight be a reminder that even the most notorious substances can sometimes be repurposed for good? Only time will tell.
As research continues, we can only hope that this is just one more step on the long road toward a cure.
To a future free from cancer,
Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team
Sources:
Dr. Markus Bernards. (2024). Study shows derivatives of thalidomide compound drive resistant cancer cells to their deaths. Cell Reports Physical Science. DOI: 10.1016/j.xcrp.2024.101960
